Literature DB >> 21672306

The Bowel Function Index for evaluating constipation in pain patients: definition of a reference range for a non-constipated population of pain patients.

M A Ueberall1, S Müller-Lissner, C Buschmann-Kramm, B Bosse.   

Abstract

Opioid-induced constipation (OIC) is a severe, persisting side-effect of opioid therapy. The Bowel Function Index (BFI(a), numerical analogue scale 0 - 100), calculated as the mean of three variables (ease of defaecation, feeling of incomplete bowel evacuation, and personal judgement of constipation) was developed to evaluate bowel function in opioid-treated patients with pain. This clinician-administered tool allows easy measurement of OIC from the patient's perspective. The purpose of this investigation was to define a reference range reflecting BFI values in non-constipated chronic pain patients who were recruited into a cross-sectional survey and asked for their perceptions of constipation. The BFI scores were assessed and compared with those of patients with confirmed OIC obtained from two previously published trials. Results were analysed and a reference range of BFI values of 0 - 28.8, into which 95% of non-constipated chronic pain patients fell, was defined. This permits discrimination between chronic pain patients with, or without, constipation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21672306     DOI: 10.1177/147323001103900106

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  31 in total

Review 1.  Oxycodone/Naloxone prolonged-release: a review of its use in the management of chronic pain while counteracting opioid-induced constipation.

Authors:  Celeste B Burness; Gillian M Keating
Journal:  Drugs       Date:  2014-03       Impact factor: 9.546

Review 2.  Pathophysiology and management of opioid-induced constipation: European expert consensus statement.

Authors:  Adam D Farmer; Asbjørn M Drewes; Giuseppe Chiarioni; Roberto De Giorgio; Tony O'Brien; Bart Morlion; Jan Tack
Journal:  United European Gastroenterol J       Date:  2018-12-14       Impact factor: 4.623

Review 3.  American Gastroenterological Association Institute Technical Review on the Medical Management of Opioid-Induced Constipation.

Authors:  Brian Hanson; Shazia Mehmood Siddique; Yolanda Scarlett; Shahnaz Sultan
Journal:  Gastroenterology       Date:  2018-10-16       Impact factor: 22.682

Review 4.  Opioid-induced constipation: advances and clinical guidance.

Authors:  Alfred D Nelson; Michael Camilleri
Journal:  Ther Adv Chronic Dis       Date:  2016-01-25       Impact factor: 5.091

Review 5.  Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.

Authors:  Michael Camilleri; Anthony Lembo; David A Katzka
Journal:  Clin Gastroenterol Hepatol       Date:  2017-05-19       Impact factor: 11.382

6.  Opioid-induced constipation reversal in response to placebo in a patient with a history of IBS receiving methadone maintenance therapy.

Authors:  Andriy V Samokhvalov; Jürgen Rehm
Journal:  BMJ Case Rep       Date:  2015-11-13

7.  A randomized, double-blind, active-controlled, double-dummy, parallel-group study to determine the safety and efficacy of oxycodone/naloxone prolonged-release tablets in patients with moderate/severe, chronic cancer pain.

Authors:  Sam H Ahmedzai; Friedemann Nauck; Gil Bar-Sela; Björn Bosse; Petra Leyendecker; Michael Hopp
Journal:  Palliat Med       Date:  2011-09-21       Impact factor: 4.762

Review 8.  Management of Opioid-Induced Constipation and Bowel Dysfunction: Expert Opinion of an Italian Multidisciplinary Panel.

Authors:  Roberto De Giorgio; Furio Massimino Zucco; Giuseppe Chiarioni; Sebastiano Mercadante; Enrico Stefano Corazziari; Augusto Caraceni; Patrizio Odetti; Raffaele Giusti; Franco Marinangeli; Carmine Pinto
Journal:  Adv Ther       Date:  2021-06-04       Impact factor: 3.845

9.  Development of opioid-induced constipation: post hoc analysis of data from a 12-week prospective, open-label, blinded-endpoint streamlined study in low-back pain patients treated with prolonged-release WHO step III opioids.

Authors:  Michael A Ueberall; Gerhard Hh Mueller-Schwefe
Journal:  J Pain Res       Date:  2015-08-10       Impact factor: 3.133

Review 10.  Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.

Authors:  Guido Fanelli; Andrea Fanelli
Journal:  Drug Des Devel Ther       Date:  2015-07-22       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.